KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Erişim
info:eu-repo/semantics/closedAccessTarih
2023Yazar
Lavie, DavidTimmerman, John
Sanz, Ramon Garcia
Kim, Won Seog
Kim, Tae Min
Avigdor, Abraham
Dierickx, Daan
Jagadeesh, Deepa
Herrera, Alex Francisco
Üst veri
Tüm öğe kaydını gösterKünye
Lavie, D., Timmerman, J., Sanz, R. G., Kim, W.S., Kim, T. M., Avigdor, A. ... Herrera, A. F. (2023). KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.Özet
...
WoS Q Kategorisi
Q1Kaynak
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)Cilt
41Sayı
16Koleksiyonlar
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6585]